Bafetinib is a potent and selective dual inhibitor of Bcr-Abl/Lyn tyrosine kinase (IC50: 5.8nM and 19nM, respectively).

Bafetinib is a specific dual Abl-Lyn inhibitor. For 79 other tyrosine kinases, Bafetinib (0.1μM) can inhibit 4 of these enzymes including Abl, Abl-related gene, Fyn, and Lyn. Bafetinib can block the autophosphorylation of Bcr-Abl. In K562 and 293T cells transfected with wt Bcr-Abl, Bafetinib shows inhibition with IC50 values of 11nM and 22nM, respectively. In the in vitro kinase assays, Bafetinib shows inhibition of a variety of Abl kinase mutants such as M244V, G250E, Y253F, and F317L. It has no effect on T315I in vitro. Bafetinib also suppresses the growth of Bcr-Abl–positive leukemic cell lines including K562, KU812, and BaF3/wt. The BaF3/E255K cells are also sensitive towards Bafetinib. Moreover, Bafetinib is highly potent to inhibit tumor growth in murine tumor models [1].